An observational study in Alzheimer Disease, sponsored by Aalborg University Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Aalborg University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Alzheimer Disease with a site in Denmark — 7 open to participants now, 13 under way, 4 of them phase 3. Alzheimer Disease · Denmark.
Among the 58 studies in Alzheimer Disease with a site in Denmark, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 53rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →7 of the 58 studies in Alzheimer Disease with a site in Denmark are open now. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Ages 60–90 · Healthy volunteers
Hoffmann-La Roche · Sites in Denmark, United States, Argentina and 12 more countries
Ages 50–90
Eidos Therapeutics, a BridgeBio company · Sites in Denmark, United States, Argentina and 21 more countries
Ages 18–75
Zealand University Hospital · Sites in Denmark
Ages 40+
Zealand University Hospital · Sites in Denmark
Ages 50+ · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 27 · Phase 4 1
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 461 across the 45 interventional studies, 100 across the 13 observational. Of the 42 that completed or were terminated, 22 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 58 have an industry lead sponsor. The 10 most frequent:
Aalborg University Hospital is the lead sponsor of 199 studies on the registry; 42 are open to participants now.
Aalborg University Hospital has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Alzheimer Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482072Rigshospitalet, DenmarkBrain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study | 2026-12 |
| NCT06570109Aalborg University HospitalFrailty Outcomes And Risk With Alzheimer's Related Dementia | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 58 studies in Alzheimer Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim of this study is to investigate the association between frailty as defined by the Fried Frailty Phenotype and risk of functional decline in patients with Alzheimer's dementia. The hypothesis is that frailty is associated with greater functional decline in community-dwelling older people with Alzheimer's dementia compared to those without frailty.
Secondary aims include investigation of long-term risk of institutionalization (through administrative follow-up) and trajectories of assessment components in future assessment.
The study is designed as a prospective cohort study. Participants in the study will undergo an assessment battery at baseline, 1 years of follow-up, and administrative follow-up for 5 years.
Participants will be recruited from patients of the Unit of Dementia at Aalborg University Hospital within 3 months of dementia diagnosis. The time frame of 3 months after diagnosis was chosen to ensure that cognitive assessment in the Unit of Dementia was reflective of patient's cognitive level and thereby ability to consent at inclusion. Patients will be eligible for inclusion if they are 65 years or older, have a diagnosis of mild or moderate Alzheimer's or mixed (Alzheimer's and vascular) dementia, live at home, and are able to walk 5 meters independently of other people (walking aids will be allowed). The severity of dementia will be defined according to score on the Mini Mental State Examination (MMSE) as it has done in other studies. According to this definition a MMSE score between 20-30 indicates mild Alzheimer's dementia and a MMSE score from 15-19 indicates moderate dementia. People with moderately severe and severe Alzheimer's dementia defined as MMSE score below 15 will not be eligible to participate.
This study aims to include community-dwelling people living at home with mild to moderate Alzheimers dementia aged 65+. Participant will be included only within 3 months of dementia diagnosis. Consecutive sampling at the Unit of Dementia in Northen Jutland in Denmark will be employed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Defined by Fried Frailty Criteria
Other: Frailty
Defined by Fried Frailty Criteria
defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
Caregiver IADL Change
Defined by caregiver reported ADL performance on the Functional Activities Questinnaire
Time frame: 1 year
Patient IADL Change
Defined by patient reported ADL performance on the Functional Activities Questinnaire
Time frame: 1 year
Caregiver BADL Change
Defined by caregiver reported ADL performance on Barthel ADL scale
Time frame: 1 year
Patient BADL Change
Defined by patient reported ADL performance on Barthel ADL scale
Time frame: 1 year
Nursing home admission
Admission to nursing home (time to event)
Time frame: 5 years
Mortality
Death (time to event)
Time frame: 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 36 months after the start.
Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 36 months is below that.
Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.